Additionally, doxycycline, an MMP inhibitor independent of its antimicrobial properties, has demonstrated efficacy in reducing MMP7 and MMP8 levels, thereby decreasing the systemic inflammatory burden and potentially preventing secondary myocardial infarctions [60]. Here, MMP8 is linked to myocardial infarction.